Document Detail


NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
MedLine Citation:
PMID:  20457867     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.
Authors:
George D Demetri; Margaret von Mehren; Cristina R Antonescu; Ronald P DeMatteo; Kristen N Ganjoo; Robert G Maki; Peter W T Pisters; Chandrajit P Raut; Richard F Riedel; Scott Schuetze; Hema M Sundar; Jonathan C Trent; Jeffrey D Wayne
Related Documents :
11399827 - Mcv as a guide to phlebotomy therapy for hemochromatosis.
2096867 - Quality-assurance monitoring in thrombolytic therapy.
15971817 - Equine endotoxaemia--a state-of-the-art review of therapy.
24892687 - Botfly larva masquerading as periorbital cellulitis: identification by point-of-care ul...
22014077 - The burden of self-reported acute gastrointestinal illness in italy: a retrospective su...
3967827 - Conflicts and complexity in inpatient geropsychiatry.
Publication Detail:
Type:  Consensus Development Conference; Journal Article    
Journal Detail:
Title:  Journal of the National Comprehensive Cancer Network : JNCCN     Volume:  8 Suppl 2     ISSN:  1540-1405     ISO Abbreviation:  J Natl Compr Canc Netw     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-05-11     Completed Date:  2010-06-08     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  101162515     Medline TA:  J Natl Compr Canc Netw     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S1-41; quiz S42-4     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use
Benzamides
DNA Mutational Analysis
Diagnostic Imaging
Gastrointestinal Stromal Tumors / pathology*,  therapy*
Gene Expression Profiling
Humans
Indoles / administration & dosage,  adverse effects,  therapeutic use
Piperazines / administration & dosage,  adverse effects,  therapeutic use
Prognosis
Pyrimidines / administration & dosage,  adverse effects,  therapeutic use
Pyrroles / administration & dosage,  adverse effects,  therapeutic use
Tumor Markers, Biological
Grant Support
ID/Acronym/Agency:
R01 CA102613/CA/NCI NIH HHS; R01 CA106588/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Benzamides; 0/Indoles; 0/Piperazines; 0/Pyrimidines; 0/Pyrroles; 0/Tumor Markers, Biological; 0/sunitinib; BKJ8M8G5HI/imatinib
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Compensatory motor control after stroke: an alternative joint strategy for object-dependent shaping ...
Next Document:  Critical role of Src-Syk-PLC{gamma}2 signaling in megakaryocyte migration and thrombopoiesis.